ADARx Pharmaceuticals, Inc. lists OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, OrbiMed Israel GP II, L.P., and OrbiMed Advisors Israel II Ltd as directors and 10% owners. Preferred stock is held directly by OrbiMed Private Investments VII, LP and OrbiMed Israel Partners II, L.P.; reported common-share equivalents reflect automatic conversion on a 1-for-1.1717 basis upon closing of the issuer’s IPO, without further consideration. The reporting entities disclaim beneficial ownership except to the extent of any pecuniary interest.
ADARx Pharmaceuticals, Inc. has three 10% owners reporting preferred holdings as of September 24, 2026. LAV Biosciences Fund V, L.P. reports Series A, B, B-1 and C holdings corresponding to 8,908,775, 1,667,469, 513,067 and 153,868 underlying common shares, respectively. LAV Fund VI, L.P. and LAV Fund VI Opportunities, L.P. each report 307,738 underlying common shares indirectly through Series C. The counts give effect to a 1-for-1.1717 reverse stock split basis; Preferred Stock converts automatically into common stock upon IPO closing without further consideration.
ADARx Pharmaceuticals, Inc. director Huang Ying reported a directly held stock option covering 267,792 common shares, with an exercise price of 8.69 per share and an expiration date of July 19, 2036. The option was granted July 20, 2026. One-quarter of the shares vest and become exercisable on July 20, 2027; the remainder vest in equal quarterly installments over the following three years, subject to continued service on each vesting date.
ADARx Pharmaceuticals, Inc. director Mary Tagliaferri reported two directly held stock-option awards, each covering 178,528 common shares. The award granted November 22, 2025 has a $6.25 exercise price and expires November 21, 2035; the award granted July 20, 2026 has an $8.69 exercise price and expires July 19, 2036. Each award vests one-quarter on its first vesting date—November 22, 2026, or July 20, 2027—with the remainder in equal quarterly installments over three years, subject to continued service on each vesting date.
ADARx Pharmaceuticals, Inc. Chief People Officer Robert William Ackles reported employee stock options covering 335,633 common shares, granted August 17, 2026, with an $8.69 exercise price and an expiration date of August 16, 2036. One-quarter of the shares vest and become exercisable on August 3, 2027; the rest vest in equal quarterly installments over three years, subject to continued service on each vesting date.
ADARx Pharmaceuticals, Inc. director Erez Chimovits reported indirect positions in four preferred-stock series held directly by OrbiMed Israel Partners II, L.P. The reported common-share amounts, giving effect to conversion, are 7,127,019 for Series A, 1,333,975 for Series B, 513,067 for Series B-1 and 256,448 for Series C. Each preferred share automatically converts into common stock on a 1-for-1.1717 basis upon the issuer’s IPO closing, without further consideration. OrbiMed Advisors Israel II Limited exercises voting and investment power through a committee comprising Chimovits, Carl L. Gordon and David P. Bonita; all three disclaim beneficial ownership except to the extent of any pecuniary interest.
ADARx Pharmaceuticals, Inc. Chief Technology Officer Zhu Rui reported 2,511,943 directly held common shares and directly held employee stock options for common stock. The options have exercise prices of $0.24, $0.56, $2.29, $3.26, $5.84, $6.31 or $7.05 per share, with expiration dates from August 19, 2030, through January 27, 2036. Footnotes describe some options as fully vested and exercisable and later grants as vesting quarterly subject to continued service.
ADARx Pharmaceuticals, Inc. reports that Chief Scientific Officer Alan Robert MacLeod holds four direct employee stock option tranches covering common shares: 513,401 at a $3.2600 exercise price, 42,673 at $5.8400, 42,673 at $7.0500, and 68,276 at $6.3100. Their expiration dates are February 25, 2033, January 16, 2034, February 11, 2035, and January 27, 2036, respectively. Each award vests in quarterly installments after an initial one-quarter vesting, subject to continued service.
ADARx Pharmaceuticals, Inc. reported that its CFO and CBO, Ryan Fisk, directly holds an employee stock option covering 865,864 common shares, with an exercise price of $6.31 per share and an expiration date of March 23, 2036. The option was granted March 24, 2026. One-quarter of the shares vest and become exercisable March 24, 2027; the remainder vest in equal quarterly installments thereafter over three years, subject to continued service on each vesting date.
ADARx Pharmaceuticals, Inc. director and 10% owner Gordon Carl L is named in connection with preferred stock held directly by OrbiMed Private Investments VII, LP and OrbiMed Israel Partners II, L.P. He disclaims beneficial ownership, except to the extent of any pecuniary interest. The positions include Series A, B, B-1 and C Preferred Stock; the reported underlying common-share amounts reflect a 1-for-1.1717 conversion basis. The preferred shares will automatically convert into common stock upon closing of the issuer’s initial public offering, without further consideration.